gvtcx

Oncotype DX Breast Cancer Testing

East Sussex Healthcare NHS Trust Published 3 Mar 2026 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£272,700
Statuscomplete
Category (CPV) 85111800
Deadline4 Feb 2026
Contract start1 Apr 2026
Contract end31 Mar 2027
Procedureselective
SME suitableNo
OCIDocds-b5fd17-6952487a-f7d5-42df-ae7a-052feb2a20e7

Award

SupplierValueDateStatus
Exact Sciences UK, Ltd. £272,700 2 Mar 2026 active

description

Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy

decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient.

Additional information:

This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
3 Mar 2026 Award (award) · be83749f-55db-4eb4-b59b-40aa06ac75c4-886769

more from East Sussex Healthcare NHS Trust

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.